Life sciences and healthcare provider research teams are increasingly using clinical Real World Data (RWD) — and for good reason. Clinical trials and studies are a robust process, and RWD is helping supplement, or in some cases supplant, them with pre-existing high-quality data in a timely and very economical manner.
Data diversity and clinical participation can also be expanded, thus enhancing widespread treatment effectiveness and safety.
Yet, with all of the positives associated with clinical RWD, it's still a relatively new frontier and all parties – regulatory, life sciences, providers, legal experts – are understandably in education mode. We have assembled a top tier thought-leader group from across these modalities who will share their insights, lessons learned, and suggested paths during this webinar.
Key learning Points:
- Why healthcare providers have entered the clinical RWD landscape
- Biggest challenges to providing regulatory-grade RWD
- Life science evaluation criteria for clinical RWD source
- Legal considerations as a clinical RWD data source or data consumer
.jpeg?width=120&height=120&name=lachance-mike-president-coo%20-%20Lauren%20Farley%20(1).jpeg)
